Abstract
Nearly all clinical trials that have attempted to develop effective strategies against ischemic stroke have failed, excluding those for thrombolysis, and most of these trials focused only on preventing neuronal loss. However, astrocytes have gradually become a target for neuroprotection in stroke. In previous studies, we showed that the newly identified molecular N-myc downstream-regulated gene 2 (Ndrg2) is specifically expressed in astrocytes in the brain and involved in some neurodegenerative diseases. However, the role of NDRG2 in ischemic stroke remained unclear. In this study, we investigated the role of NDRG2 in middle cerebral artery occlusion (MCAO)-induced focal cerebral ischemia and in oxygen–glucose deprivation (OGD)-induced cellular apoptosis in the M1800 astrocyte cell line. NDRG2 mRNA and protein expression began to increase at 6 and 2 h after reperfusion and peaked at 24 h in the ischemic penumbra and in M1800 cells, as detected by RT-PCR and Western blotting. Double immunofluorescence staining showed that the number of apoptotic cells increased as the NDRG2-positive signal increased and that the NDRG2 signal was sometimes co-localized with TUNEL-positive cells and translocated from the cytoplasm to the nucleus in both the ischemic penumbra and the M1800 cells. Using a lentivirus, we successfully constructed two stable astrocytic cell lines in which NDRG2 expression was significantly up- or down-regulated. NDRG2 silencing had a proliferative effect and reduced the percentage of apoptotic cells, reactive oxygen species (ROS) production, and cleaved Caspase-3 protein expression following OGD, whereas NDRG2 over-expression had the opposite effects. In conclusion, NDRG2 is involved in astrocyte apoptosis following ischemic–hypoxic injury, and inhibiting NDRG2 expression significantly reduces ROS production and astrocyte apoptosis. These findings provide insight into the role of NDRG2 in ischemic–hypoxic injury and provide potential targets for future clinical therapies for stroke.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Over the past two decades, over 1000 clinical trials of stroke treatments have failed to demonstrate a benefit, with the exception of thrombolytics [1]. Although many targets have been pursued, including antioxidants, calcium channel blockers, glutamate receptor blockers, and neurotrophic factors, the focus has often been on the mechanisms of neuronal injury because neurons are more vulnerable to the detrimental effects of ischemia due to the loss of energy and nutrition. In fact, both energy and nutritional resources are transported by astrocytes, which are the most abundant cell type in the brain and play key roles in the physiology and pathology of the central nervous system (CNS) [2]. Astrocytes perform various functions including the mediation of synaptic transmission through removal of the majority of glutamate from the synaptic cleft, balance of ions and fluid in the extracellular space, formation of the blood–brain barrier, control of energy metabolism, and regulation of blood flow through contact with the brain vasculature [3–5]. Therefore, astrocyte dysfunction is now considered one of the key factors in neuron death after ischemic stroke [6]. Previous studies show that astrocyte apoptosis, which seriously impairs astrocyte functions, contributes largely to ischemia stroke-induced neuronal injury [7]. Thus, the investigation of astrocyte-specific molecular mechanisms to inhibit astrocyte apoptosis might provide novel targets for the development of neuroprotective strategies for ischemic stroke.
N-Myc downstream-regulated gene 2 (NDRG2) was first identified in a normal human brain cDNA library in 2001 [8] and was subsequently found to be highly expressed in the rat brain [9]. In a recent study, we demonstrated that NDRG2 was primarily expressed in astrocytes in the mouse brain [10]. Another recent study showed that NDRG2-positive astrocytes were more abundant and more evenly distributed in the brain than glial fibrillary acidic protein (GFAP)-positive astrocytes [11], which is a classic astrocyte marker. Thus, NDRG2 is considered a new marker for astrocytes. However, the function of NDRG2 in astrocytes remains unclear.
Several studies have shown that NDRG2 is related to several important functions and pathophysiological processes in the CNS. Mitchelmore et al. [12] observed that both the RNA and protein expression levels of NDRG2 were up-regulated in patients with Alzheimer’s disease (AD). Takahashi et al. [13] reported down-regulation of NDRG2 expression in the rat frontal cortex after long-term antidepressant administration and repeated electroconvulsive treatment. Furthermore, increased NDRG2 protein expression is found in the hippocampus of chronically stressed rats [14], and NDRG2 is also associated with frontotemporal lobar degeneration [15]. Our previous study was the first to report the spatial–temporal expression of NDRG2 in the rat brain after transient focal cerebral ischemia [16] and indicated that NDRG2 in astrocytes is involved in the development of the pathological processes of cerebral ischemia. However, the mechanisms that underlie the effects of NDRG2 in cerebral ischemic injury remain to be elucidated, and NDRG2 may become a new molecular target for the treatment of ischemic stroke.
Materials and Methods
Animals
Forty 6-month-old male C57BL/6 mice (23–25 g) were obtained from the Laboratory Animal Center of the Fourth Military Medical University. These mice were randomly assigned to one of the following five groups (n = 8 in each group): the sham-operated group or the 2-, 6-, 12-, or 24-h ischemia/reperfusion (I/R) group. The mice in the sham group received the same surgery, but middle cerebral artery occlusion (MCAO) was not performed. The mice in the I/R groups were subjected to 60-min MCAO and were then were killed at 2, 6, 12, and 24 h after reperfusion. All animal experimental procedures followed a protocol approved by the Ethics Committee for Animal Experimentation of the Fourth Military Medical University, China.
MCAO
MCAO was performed as previously described [17]. Cerebral blood flow was monitored using laser Doppler flowmetry (PeriFlux 5000; Perimed AB, Järfälla, Sweden). During surgery, occlusion was considered successful when blood flow declined to less than 15 % of the pre-ischemic baseline level; otherwise, the animals were discarded. Following 1 h of transient occlusion, cerebral blood flow was restored by removing the nylon suture for 2, 6, 12, and 24 h. Physiological parameters, such as blood pressure and blood gas, were monitored.
Immunofluorescence Double-Labeling
Paraffin sections were deparaffinized in xylene and rehydrated. The sections were incubated with proteinase K (10 μg/mL) for 15 min at 37 °C for antigen retrieval, and nonspecific antibody-binding sites were blocked with 1 % BSA–PBS. The sections were incubated with an anti-NDRG2 rabbit monoclonal antibody (1:100; Cell Signaling Technology, USA) and an anti-GFAP mouse monoclonal antibody (1:400; Cell Signaling Technology) in 1 % BSA–PBS overnight at 4 °C. The sections were then washed in TBS and incubated with an anti-mouse fluorescein isothiocyanate (FITC)-tagged secondary antibody (1:200; CWBIO, Peking, China) and an anti-rabbit CY3-tagged secondary antibody (1:200; CWBIO, Peking, China) for 2 h at room temperature. 4′,6-Diamidino-2-phenylindole (DAPI) (1 ng/μL) was used to stain the nuclei. The sections were mounted with 50 % glycerol and examined under a fluorescence microscope.
Cell Culture
MA1800-57 cells were purchased from Scinecell and cultured at 37 °C in conditions of 5 % CO2 and 95 % oxygen in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % fetal bovine serum, streptomycin (100 μg/ml), and penicillin (100 units/mL). The cells were divided into five groups: (1) the Con group: cells without lentiviral infection; (2) the KD-NC group: cells infected with a negative control lentivirus; (3) the KD group: cells infected with a lentivirus that knocked down NDRG2 expression; (4) the OE-NC group: cells infected with a negative control lentivirus (LEN-Lacz); and (5) the OE group: cells infected with a lentivirus that up-regulated NDRG2 expression (LEN-NDRG2).
Construction of a Stable Cell Line with Down-regulated NDRG2 Expression
The lentivirus that could disrupt NDRG2 expression was purchased from Genepharma Company (Shanghai, China). The NDRG2-targeting sequence was 5′-GGGATATGCAAGAGATCATAC-3′, and the negative control sequence was 5′-TTCTCCGAACGTGTCACGT-3′. The lentivirus contained a green fluorescent protein (GFP) reporter gene, which resulted in stable green fluorescence in transfected cells. Briefly, 450 μl of cell culture medium and 50 μl of lentivirus were added to M1800 cells in 24-well plates. After 48–72 h, we observed that 70–80 % of the cells expressed GFP, as detected by fluorescence microscopy (Olympus, Tokyo, Japan; Supplemental Fig. 1), verifying successful lentiviral transfection. Then, we cultured the transfected cells for proliferation and screened them for green fluorescence using flow cytometry. Western blotting confirmed that the cell line exhibited stable down-regulation of NDRG2 expression (Supplemental Fig. 2).
Construction of a Stable Cell Line with Up-regulated NDRG2 Expression
To produce the lentivirus, 293T cells were co-transfected with pLEN-NDRG2 or pLEN-Lacz. The plasmids were amplified in E. coli DH5 cells, purified using a Plasmid Maxi Kit (Qiagen, Valencia, CA, USA), and transfected into 70 % confluent 293T cells using Lipofectamine 2000 (Invitrogen). Lentiviral particles were harvested from the supernatant 72 h after the transfection and purified by ultracentrifugation. These particles are hereafter referred to as LEN-NDRG2 and LEN-Lacz (negative control). Stably infected M1800 cells were selected using blasticidin (10 μg/ml; Sigma, USA), which killed the uninfected cells. Western blotting confirmed that the LEN-NDRG2-infected M1800 cells stably over-expressed NDRG2 (Supplemental Fig. 2).
EdU Proliferation Assay
The proliferative capacity of the different groups of cells was determined using the Click-iT EdU (5-ethynyl-20-deoxyuridine) Alexa Fluor 594 Imaging Kit (Invitrogen, USA) according to the manufacturer’s protocol. Briefly, cells that were cultured in 96-well plates were incubated with 10 μM EdU for 3 h before they were fixed, permeabilized, and stained with EdU. Cell nuclei were stained with DAPI (1 ng/μl) for 10 min. EdU is a nucleoside analog of thymidine that is only incorporated into DNA during active DNA synthesis in proliferating cells. After EdU was incorporated into the cells, a fluorescent molecule was added that reacted specifically with EdU, enabling fluorescent visualization of proliferating cells. The percentage of EdU-positive cells was calculated from five random fields in three wells.
Cell Cycle Analysis
The cell cycle was assessed by flow cytometry. The cells of different groups were collected by trypsinization and centrifuged twice in PBS. The cells were then fixed in pre-cooled 70 % ethanol at −20 °C and stained with propidium iodide (PI) solution. The DNA content was determined by flow cytometry using CellQuest Software. For each sample, 10,000 events were counted (FACSCalibur, Becton–Dickinson, USA). The percentage of cells that were in a particular cell cycle stage was calculated using ModFit software (Becton–Dickinson, USA).
Oxygen and Glucose Deprivation and Reperfusion
The cells of different groups were washed twice in DMEM without glucose (oxygen and glucose deprivation (OGD) medium) and transferred to DMEM without glucose. Then, the cells were transferred to a modular incubator chamber. The chamber was flushed with a 95 % N2/5 % CO2 gas mixture at 3 L/min for 30 min at room temperature. The chamber was then sealed and placed in a 37 °C container. OGD was carried out for 4 h. Following OGD, the cells were incubated in DMEM with glucose (without fetal bovine serum) for an additional 2, 6, 12, and 24 h of reperfusion under normal conditions and then collected for subsequent analysis.
RT-PCR
For reverse transcription RT-PCR, 50 mg of tissue (n = 5 in each group) and cells with different reperfusion times (2, 6, 12, and 24 h as well as sham) were collected immediately. Total RNA was isolated from each sample using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and then quantified. Two micrograms of total RNA was reverse-transcribed using reverse transcriptase (Promega, Madison, WI, USA) according to the manufacturer’s instructions. All PCR experiments were performed using Taq polymerase (Promega) with the following primers: ndrg2 sense (5′-CAGAACTTCGTGCGGGTTCA-3′), ndrg2 antisense (5′-GAATGTAGGCTCCGGCTCCA-3′), GAPDH sense (5′-CATCCGTAAAGACCTCTATGCCAAC-3′), and GAPDH antisense (5′-ATGGAGCCACCGATCCACA-3′). The PCR products were resolved on a 1 % agarose gel containing ethidium bromide, and the bands were visualized using ultraviolet light.
Measurement of Reactive Oxygen Species
After exposed to oxygen and glucose deprivation and reperfusion (OGD-R), different groups of cells were washed with PBS and loaded with DCFH-DA (5 μM) from Reactive Oxygen Species Assay Kit (Beyotime Institute of Biotechnology, Jiangsu, China) for 40 min. After a further wash with PBS, cell suspensions were collected into a 96-well flat bottom black plate to determine the relative fluorescent intensity (RFI, λex 485 nm, λem 535 nm) by Tecan GENios fluorescence microplate reader. The DMEM medium was used as blank. The RFI over control was calculated as the measured reactive oxygen species (ROS) production levels.
Cell Fraction Assay
Twenty-four hours after the cells were exposed to OGD, nuclear extracts were prepared in accordance with the protocol of the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Pierce, Rockford, IL, USA). Briefly, M1800 cells were washed twice with ice-cold PBS, and 200 ml of ice-cold cytoplasmic extraction reagent I was added. The cells were incubated on ice for 10 min, and then 11 ml of ice-cold cytoplasmic extraction reagent II was added. The cells were incubated on ice for 1 min, and the tube was then centrifuged for 5 min at maximum speed in a microcentrifuge (16,000 × g). The supernatant fraction (cytoplasmic extract) was immediately transferred to a clean pre-chilled tube, and 100 ml of ice-cold nuclear extraction reagent was added to the insoluble fraction by vortexing for 15 s every 10 min for a total of 40 min. The tube was centrifuged at maximum speed in a microcentrifuge for 10 min. The nuclear extract fraction was then moved to a clean pre-chilled tube. All extracts were analyzed by Western blotting.
Western Blot Analysis
For Western blot analysis, 50 mg of tissues (n = 5 in each group) and cells with different reperfusion times (sham and 2, 6, 12, and 24 h) were lysed in modified radioimmunoprecipitation assay buffer. The protein concentration was measured using the bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA). Proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Hybond ECL nitrocellulose membranes (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK). Mouse anti-NDRG2 (1:1000; Cell Signaling Technology), rabbit anti-cleaved Caspase-3 (1:1000; Cell Signaling Technology), rabbit anti-Caspase-3 (1:1000; Cell Signaling), rabbit anti-Histone H2A.X (1:300; Signalway Antibody, USA), mouse anti-β-actin (1:1000; Cell Signaling), and mouse anti-GAPDH antibodies (1:1000; Cell Signaling) were used for immunoblotting. The membranes were then incubated with an HRP-conjugated secondary antibody for 2 h. Protein bands were visualized using the LI-COR Odyssey System (LI-COR Biotechnology, USA).
Flow Cytometric Analysis
After OGD and 24 h of reperfusion, cell apoptosis was assayed by flow cytometry. Briefly, the cells of different groups were washed with 1× annexin V-FITC binding buffer prior to being stained with annexin V-FITC and PI for 15 min at room temperature in the dark. The stained cells were immediately analyzed using flow cytometry. Apoptotic and necrotic cells were quantified by annexin V binding and PI uptake, respectively. The annexin V-FITC+/PI– cell populations were considered to represent apoptotic cells.
TUNEL and NDRG2 Immunofluorescence Double-Labeling
Apoptosis was quantified using a commercially available fluorescent terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) kit in accordance with the manufacturer’s protocol (Roche Diagnostics Corporation, USA). Coronal brain sections from mice that were subjected to MCAO and coverslips with M1800 cells that were exposed to OGD-R were incubated with a rabbit anti-NDRG2 antibody (1:100; Cell Signaling) and an anti-rabbit CY3-tagged secondary antibody and then stained with DAPI (1 ng/μL). The sections were mounted with 50 % glycerol and examined under a fluorescence microscope.
Statistical Analysis
The data are presented as the mean ± S.D. Differences among the groups were analyzed using one-way ANOVA. Differences between two groups were analyzed using a two-tailed Student’s t test with SPSS 13. A p value <0.05 was considered statistically significant.
Results
Temporal Expression of NDRG2 in the Ischemic Penumbra
Compared to the expression in the sham-operated group, in the ischemia–reperfusion (I/R) groups, NDRG2 mRNA (Fig. 1a) and protein (Fig. 1b) expression in the ischemic penumbra began to significantly increase at 6 h after reperfusion and peaked at 24 h (*p < 0.05; Fig. 1c).
We detected NDRG2 expression in different parts of the ischemic penumbra (cortex, striatum, hippocampus) at 24 h after reperfusion. Compared to the expression in the sham-operated group, in the I/R groups, NDRG2 protein expression in the cortex and striatum of the ischemic penumbra significantly increased at 24 h after reperfusion (*p < 0.05; Fig. 2), while NDRG2 protein expression in the hippocampus of the ischemic penumbra has no significant difference compared to the sham-operated group (Fig. 2).
Location and Expression of NDRG2 in the Ischemic Penumbra
NDRG2 protein (red) was co-localized with GFAP protein (green) in both the sham-operated and ischemic brains, consistent with an astrocytic localization. NDRG2 expression in the ischemic penumbra at 24 h after reperfusion was higher than the expression in the sham-operated group (Fig. 3). Furthermore, NDRG2 protein expression was weak in the nucleus and strong in the cytoplasm in the sham-operated group (Fig. 4). However, the NDRG2 protein expression was strong in the nucleus and the NDRG2 protein (red) was co-localized with DAPI staining (blue) in the ischemic penumbra at 24 h after reperfusion.
Cellular NDRG2 Co-localization with Apoptotic Cells
TUNEL staining showed that few apoptotic cells were present in the sham hemisphere, whereas the number of apoptotic cells in the ischemic penumbra was significantly increased at 24 h after reperfusion (Fig. 5). Furthermore, double immunofluorescence for TUNEL and NDRG2 demonstrated that some of the TUNEL-positive cells were co-localized with NDRG2-positive cells in the ischemic penumbra following I/R.
Up-regulation of NDRG2 Expression Inhibited the Proliferation of M1800 Cells
We successfully established cell lines in which NDRG2 expression was stably up- and down-regulated, as verified by Western blot analysis (Supplementary Fig. 2).
Cell proliferation was analyzed using an EdU incorporation assay and flow cytometric analysis. As shown in Fig. 6b, the percentage of EdU-positive cells was 46.49 ± 4.49, 48.09 ± 4.80, and 47.06 ± 4.34 % in the Con, KD-NC, and OE-NC groups, respectively, and there were no significant differences between these three groups. Down-regulation of NDRG2 expression in the KD group induced a significant increase in the percentage of EdU-positive cells (to 63.31 ± 5.09 %) compared with that in the KD-NC group (*p < 0.05). However, in the OE group, the percentage of EdU-positive cells significantly decreased (to 33.31 ± 4.95 %) compared with that in the OE-NC group (#p < 0.05).
The flow cytometry results were consistent with those of the EdU incorporation assay. As shown in Fig. 7b, 45.73 ± 2.84, 45.98 ± 3.81, and 46.47 ± 4.01 % of cells were in S phase in the Con, KD-NC, and OE-NC groups, respectively, and 52.37 ± 3.51, 54.05 ± 2.15, and 52.81 ± 2.90 % of cells were in either S + G2 phase. There were no significant differences between these three groups. In the KD group, down-regulation of NDRG2 expression induced a significant increase in the percentage of cells that were in S phase and that were in either S + G2 phase, to 55.36 ± 1.99 and 62.06 ± 3.57 %, respectively, compared with those in the KD-NC group (*p < 0.05). However, in the OE group, the percentage of cells that were in S phase and that were in either S + G2 phase was significantly decreased, to 36.42 ± 2.94 and 43.09 ± 2.55 %, respectively, compared with those in the OE-NC group (#p < 0.05).
Temporal Expression of NDRG2 in M1800 Cells Exposed to OGD-R
RT-PCR and Western blot were performed to evaluate the changes in NDRG2 expression that occurred in the astrocyte lines after OGD exposure. NDRG2 expression was significantly up-regulated in a time-dependent manner following OGD. Compared with the expression in the Con group, in the OGD group, both NDRG2 mRNA (Fig. 8a) and protein (Fig. 8b) expression began to increase 2 h after OGD and peaked at 24 h after OGD (*p < 0.05; Fig. 8c).
In M1800 Cells, NDRG2 Was Translocated from the Cytoplasm to the Nucleus After OGD-R
As shown in Fig. 9a, in normal M1800 cells, NDRG2 was mainly co-localized with GFAP and there was little overlap with DAPI, indicating that the expression of NDRG2 was confined to the cytoplasm under normal conditions. However, the NDRG2 signal was markedly enhanced in the nuclei at 24 h after OGD exposure. The shift in NDRG2 expression indicated that NDRG2 was translocated from the cytoplasm to the nucleus, which was probably induced by the stress of OGD.
To further demonstrate the nuclear translocation of NDRG2 upon OGD exposure, a cell fraction assay was performed. As shown in Fig. 9b, under normal conditions (sham group), NDRG2 was expressed mainly in the cytoplasm and could hardly be detected in the nuclei. After the cells were exposed to OGD, NDRG2 expression in both the nucleus and cytoplasm was sharply increased (OGD group).
NDRG2 Promoted the Apoptosis of M1800 Cells Exposed to OGD-R
Flow cytometric analysis was used to assess the effect of NDRG2 on apoptosis after the cells were exposed to OGD-R (Fig. 10). In the Con, KD-NC, and OE-NC groups, the total apoptotic index was 16.10 ± 1.77, 19.70 ± 2.55, and 19.70 ± 2.62 %, respectively. There were no significant differences between these three groups. Down-regulation of NDRG2 expression (KD group) attenuated OGD-R-induced cell apoptosis to 9.73 ± 2.54 % (**p < 0.01 vs. the KD-NC group). Conversely, over-expression of NDRG2 (OE group) increased OGD-R-induced apoptosis to 31.83 ± 4.92 % (#p < 0.05 vs. the OE-NC group).
As shown in Fig. 11, the M1800 cells exhibited stronger TUNEL-positive staining after OGD exposure, indicating that OGD induced cell apoptosis. Furthermore, the NDRG2 staining was co-localized with the TUNEL staining. However, down-regulation of NDRG2 expression (KD group) alleviated the OGD-induced TUNEL-positive staining, and over-expression of NDRG2 increased the OGD-induced TUNEL-positive staining.
NDRG2 Increased ROS Levels and Cleaved Caspase-3 Expression in M1800 Cells Exposed to OGD-R
As shown in Fig. 12, compared with those of the cells in the KD-NC group, the ROS levels in the cells in the KD group were significantly reduced after the cells were exposed to OGD-R (*p < 0.05), and over-expression of NDRG2 (OE group) significantly increased ROS levels (#p < 0.05 vs. the OE-NC group). No significant differences were observed between the Con, KD-NC, and OE-NC groups.
The results of the Western blot analysis of the protein expression of cleaved Caspase-3 (Fig. 13), which is a pro-apoptosis protein, show that compared with those of the cells in the KD-NC group, the expression levels of cleaved Caspase-3 protein in the cells in the KD group were significantly reduced after the cells were exposed to OGD-R (*p < 0.05), and over-expression of NDRG2 (OE group) significantly increased cleaved Caspase-3 protein expression (#p < 0.05 vs. the OE-NC group). No significant differences were observed between the Con, KD-NC, and OE-NC groups.
Discussion
Although many clinical trials of stroke patients have been completed, none of the evaluated therapeutics were shown to be protective, except thrombolytics [1, 18]. Importantly, the majority of the failed trials only targeted neuron-specific injury mechanisms [19]. A large body of work has shown that astrocytes play key roles in both normal and pathological CNS functioning, and astrocytes are now thought to be important potential targets for stroke treatment [6]. Previous studies show that ischemia–hypoxia-induced astrocyte apoptosis, which seriously impairs astrocyte normal functions, contributes largely to neuronal injury [7]. The ischemic penumbra is the target for therapeutic interventions because salvage of this tissue is associated with neurological improvement and recovery [20]. Therefore, experimental approaches that reduce astrocyte apoptosis and enhance the function and survival of astrocytes in the ischemic penumbra may serve as a novel strategy against stroke.
NDRG2 was first identified in 2001 [8], and our previous studies showed that NDRG2 is specifically expressed in CNS astrocytes [10, 21]. Several studies have demonstrated that NDRG2 is involved in AD [12], antidepressant treatments [13, 22], social stress [14], and frontotemporal lobar degeneration [15], demonstrating its role in pathological processes in the CNS. However, the role of NDRG2 in ischemic stroke has rarely been explored.
In the present study, we found that in the ischemic penumbra of mice, NDRG2 mRNA and protein expression was significantly increased at 6 h after reperfusion and peaked at 24 h. In in vitro experiments, we found that NDRG2 expression was significantly increased at 2 h after reperfusion and peaked at 24 h in M1800 cells. In a previous study [16], we found that in the ischemic penumbra of rats, NDRG2 expression was increased at 4 h after reperfusion and peaked at 24 h but then was decreased at 72 h. The difference may be due to the duration of the MCAO surgery as well as species differences between rats and mice. In addition, we found that in the cortex and striatum of the ischemic penumbra, which are more sensitive than the hippocampus to MCAO injury, NDRG2 protein expression significantly increased at 24 h after reperfusion. These results indicate that NDRG2 plays an important role in the pathogenesis of cerebral ischemia.
In the current study, we found that both in the ischemia and in M1800 cells, some NDRG2 signals were translocated from the cytoplasm to the nucleus after I/R or OGD-R. Nuclear translocation is a key step in cell signal transduction that frequently activates the transcription of genes involved in cellular differentiation and apoptosis. Based on the results described above, we hypothesized that NDRG2 may activate its downstream targets to regulate cell apoptosis following OGD-R. The activation of certain transcription factors leads to the translocation of molecules from the cytoplasm to the nucleus. However, the mechanisms that underlie NDRG2 nuclear translocation remain unclear. Previous studies found that residues 101–178 of NDRG2 or the a6 helix of hNDRG2 might contribute to its translocation [23, 24]. Regardless, NDRG2 nuclear translocation indicates that NDRG2 plays an important role in cell signal transduction following OGD-R.
Ischemic injury peaked at 24 h after I/R in both the in vivo and in vitro experiments, suggesting that NDRG2 may contribute to cell damage in the ischemic penumbra. NDRG2 is very similar to NDRG1, which has been linked to apoptosis and may be an apoptosis-inducible factor [22]. Thus, we investigated the relationship between NDRG2 expression and cell apoptosis in the ischemic penumbra following I/R and in M1800 cells exposed to OGD-R. Our results showed that as the number of NDRG2-positive cells increased in the ischemic penumbra and following OGD-R, the number of TUNEL-positive cells also increased. Importantly, we also found that NDRG2 was co-localized with the TUNEL-positive cells. These results demonstrated that NDRG2 was associated with the cell apoptosis induced by ischemia–hypoxia injury. To further explore the relationship between NDRG2 and cell apoptosis, we first constructed two stable astrocytic cell lines in which NDRG2 expression was significantly up- or down-regulated using a lentivirus. We found that NDRG2 over-expression significantly increased apoptotic cell numbers after OGD-R, whereas silencing NDRG2 expression had the opposite effect, which indicates that NDRG2 expression induced astrocyte apoptosis after ischemia–hypoxia injury. And ischemia–hypoxia could cause oxidative stress, which produces a lot of ROS and triggers the process of cell apoptosis [25]. Thus, we detected the effect of NDRG2 on astrocyte ROS production and found that NDRG2 over-expression significantly increased ROS production and cleaved Caspase-3 protein expression after OGD-R, whereas silencing NDRG2 expression had the opposite effect. These results indicate that NDRG2 expression promote astrocyte apoptosis by increasing ROS production. However, the underlying mechanism remains unclear and warrants further study.
Besides oxidative stress, there may be some other signal pathways involved in NDRG2-induced astrocyte apoptosis. Liu et al. [26] showed that NDRG2 is involved in p53-mediated apoptosis, and p53 also acts as a master regulator of cell death by inducing apoptosis [27]. A previous study reported that NDRG2 is a novel target of hypoxia-inducible factor-1 (HIF-1), which is necessary for hypoxia-induced apoptosis in A549 cells [23]. HIF-1 also plays an important role in stroke by regulating genes such as erythropoietin and VEGF [28]. Thus, it is possible that NDRG2 acts as p53 or HIF-1 target gene to regulate ischemia-induced apoptosis.
After ischemia, astrocytes support neurons by providing antioxidant protection [29], substrates for neuronal metabolism [30], and glutamate clearance REF; accordingly, impaired astrocyte function can amplify neuronal death [31]. In previous studies, we found that sevoflurane and electroacupuncture pre-conditioning inhibited NDRG2 up-regulation and nuclear translocation in astrocytes, resulting in increased cerebral ischemic tolerance by inhibiting astrocyte apoptosis [32, 33]. A recent study found attenuated neuronal death in ndrg2 knock-out (ndrg2 −/−) mice after cortical stab injury [34]. Therefore, the use of NDRG2 as a molecular target for the reduction of astrocyte apoptosis may become a new therapeutic strategy for ischemic stroke.
In addition, because NDRG2 has been shown to be a pro-differentiative and anti-proliferative gene in previous cancer research and is now considered a tumor suppressor [24], we examined the effect of NDRG2 on cell proliferation and found that NDRG2 over-expression significantly inhibited the rate of cell proliferation, consistent with studies of human glioblastomas infected with Ndrg2 cDNA [35]. Takeichi et al. [36] found that in cultured astrocytes, silencing of the Ndrg2 gene significantly enhanced the numbers of cells that incorporated 5-bromo-2′-deoxy-uridine (BrdU) that were positive for proliferating cell nuclear antigen (PCNA) by enhancing the transcription of cell cycle molecules, such as CyclinB1 and CyclinE. However, the particular mechanism underlying the effect of NDRG2 on cell growth must be further defined.
This study had some limitations, and certain questions still remain. First, we selected only one time point (24 h after reperfusion) at which to evaluate the role of NDRG2 in the ischemic penumbra. This time point represents the acute phase of reperfusion, but the involvement of NDRG2 in the late phase of reperfusion (>72 h after reperfusion) remains unknown and warrants further study. Second, we did not explore the role of NDRG2 in astrocyte–neuron interactions, which might be an even more important mechanism. Hence, we plan to use ndrg2 −/− mice to investigate the role of NDRG2 in ischemic stroke in future studies. Third, astrocytes exhibit many cellular responses to ischemic injury, including influencing material and energy metabolism [30], glutamate excitotoxicity [37], and so forth. However, whether the increase in NDRG2 expression is related to these astrocyte functions remains unknown, and this will be the focus of our future work.
In conclusion, the current study demonstrated that up-regulation of the astrocyte-specific protein NDRG2 in the ischemic penumbra and in astrocytes exposed to OGD-R is involved in astrocyte apoptosis and that inhibiting NDRG2 expression significantly reduced ROS production and astrocyte apoptosis following exposure to OGD-R. Although further investigations are needed to elucidate the detailed signaling cascades underlying the NDRG2 pathway, our findings provide potential targets for future clinical therapies for stroke.
Abbreviations
- Ndrg2:
-
N-Myc downstream-regulated gene 2
- MCAO:
-
Middle cerebral artery occlusion
- OGD:
-
Oxygen–glucose deprivation
- CNS:
-
Central nervous system
- GFAP:
-
Glial fibrillary acidic protein
- ROS:
-
Reactive oxygen species
References
Marder VJ, Jahan R, Gruber T, Goyal A, Arora V (2010) Thrombolysis with plasmin: implications for stroke treatment. Stroke 41:S45–S49. doi:10.1161/STROKEAHA.110.595157
Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol 119:7–35. doi:10.1007/s00401-009-0619-8
Iadecola C, Nedergaard M (2007) Glial regulation of the cerebral microvasculature. Nat Neurosci 10:1369–1376. doi:10.1038/nn2003
Brown AM, Ransom BR (2007) Astrocyte glycogen and brain energy metabolism. Glia 55:1263–1271. doi:10.1002/glia.20557
Perea G, Navarrete M, Araque A (2009) Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32:421–431. doi:10.1016/j.tins.2009.05.001
Barreto G, White RE, Ouyang Y, Xu L, Giffard RG (2011) Astrocytes: targets for neuroprotection in stroke. Cent Nerv Syst Agents Med Chem 11:164–173. doi:10.2174/187152411796011303
Takuma K, Baba A, Matsuda T (2004) Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 72:111–127. doi:10.1016/j.pneurobio.2004.02.001
Deng YC, Yao LB, Liu XP (2001) Exploring a new gene containing ACP like domain in human brain and expression of it in E. coli. Prog Bichem Biophys 28:72–76
Boulkroun S, Fay M, Zennaro MC, Escoubet B, Jaisser F, Blot-Chabaud M, Farman N, Courtois-Coutry N (2002) Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J Biol Chem 277:31506–31515. doi:10.1074/jbc.M200272200
Ma YL, Qin P, Feng DY, Li Y, Zhang LX, Liu ZY, Yin AQ, Tang WH et al (2014) Estrogen regulates the expression of Ndrg2 in astrocytes. Brain Res 1569:1–8
Flügge G, Araya-Callis C, Garea-Rodriguez E, Stadelmann-Nessler C, Fuchs E (2014) NDRG2 as a marker protein for brain astrocytes. Cell Tissue Res 357:31–41. doi:10.1007/s00441-014-1837-5
Mitchelmore C, Büchmann-Møller S, Rask L, West MJ, Troncoso JC, Jensen NA (2004) NDRG2: a novel Alzheimer’s disease associated protein. Neurobiol Dis 16:48–58. doi:10.1016/j.nbd.2004.01.003
Takahashi K, Yamada M, Ohata H, Momose K, Higuchi T, Honda K, Yamada M (2005) Expression of Ndrg2 in the rat frontal cortex after antidepressant and electroconvulsive treatment. Int J Neuropsychopharmacol 8:381–389. doi:10.1017/S1461145705005134
Araya-Callís C, Hiemke C, Abumaria N, Flugge G (2012) Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus. Psychopharmacology (Berlin) 224:209–222. doi:10.1007/s00213-012-2741-x
Herskowitz JH, Seyfried NT, Duong DM, Xia Q, Rees HD, Gearing M, Peng J, Lah JJ et al (2010) Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. J Proteome Res 9:6368–6379. doi:10.1021/pr100666c
Li Y, Shen L, Cai L, Wang Q, Hou W, Wang F, Zeng Y, Zhao G et al (2011) Spatial-temporal expression of NDRG2 in rat brain after focal cerebral ischemia and reperfusion. Brain Res 1382:252–258. doi:10.1016/j.brainres.2011.01.023
Yang Q, Yan W, Li X, Hou L, Dong H, Wang Q, Dong H, Wang S et al (2012) Activation of canonical notch signaling pathway is involved in the ischemic tolerance induced by sevoflurane preconditioning in mice. Anesthesiology 117:996–1005. doi:10.1097/ALN.0b013e31826cb469
Blakeley JO, Llinas RH (2007) Thrombolytic therapy for acute ischemic stroke. J Neurol Sci 261:55–62. doi:10.1016/j.jns.2007.04.031
Howells DW, Porritt MJ, Rewell SS, O’Collins V, Sena ES, van der Worp HB, Traystman RJ, Macleod MR (2010) Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab 30:1412–1431. doi:10.1038/jcbfm.2010.66
Weinstein PR, Hong S, Sharp FR (2004) Molecular identification of the ischemic penumbra. Stroke 35(11 Suppl 1):2666–2670. doi:10.1161/01.STR.0000144052.10644.ed
Hu XL, Liu XP, Deng YC, Lin SX, Wu L, Zhang J, Wang LF, Wang XB et al (2006) Expression analysis of the NDRG2 gene in mouse embryonic and adult tissues. Cell Tissue Res 325:67–76. doi:10.1007/s00441-005-0137-5
Nichols NR (2003) Ndrg2, a novel gene regulated by adrenal steroids and antidepressants, is highly expressed in astrocytes. Ann N Y Acad Sci 1007:349–356. doi:10.1196/annals.1286.034
Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S et al (2008) NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem 21:239–250. doi:10.1159/000113765
Hwang J, Kim Y, Kang HB, Jaroszewski L, Deacon AM, Lee H, Choi WC, Kim KJ et al (2011) Crystal structure of the human N-Myc downstream-regulated gene 2 protein provides insight into its role as a tumor suppressor. J Biol Chem 286:12450–12460. doi:10.1074/jbc.M110.170803
Hou CW, Lin YT, Chen YL, Wang YH, Chou JL, Ping LY, Jeng KC (2012) Neuroprotective effects of carnosic acid on neuronal cells under ischemic and hypoxicstress. Nutr Neurosci 15:257–263. doi:10.1179/1476830512Y.0000000021
Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, Wu Y et al (2008) N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res 36:5335–5349. doi:10.1093/nar/gkn504
Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW (2002) Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 1:289–298. doi:10.1016/S1535-6108(02)00047-8
Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, Schumann-Bard P (2002) Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 22:393–403. doi:10.1097/00004647-200204000-00003
Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384:505–516. doi:10.1515/BC.2003.059
Rossi DJ, Brady JD, Mohr C (2007) Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 10:1377–1386. doi:10.1038/nn2004
Nedergaard M, Dirnagl U (2005) Role of glial cells in cerebral ischemia. Glia 50:281–286. doi:10.1002/glia.20205
Wang F, Gao Z, Li X, Li Y, Li X, Zhong H, Xu N, Cao F et al (2013) NDRG2 is involved in anti-apoptosis induced by electroacupuncture pretreatment after focal cerebral ischemia in rats. Neurol Res 35:406–414. doi:10.1179/1743132813Y.0000000159
Li X, Luo P, Wang F, Yang Q, Li Y, Zhao M, Wang S, Wang Q et al (2014) Inhibition of N-myc downstream-regulated gene-2 is involved in an astrocyte-specific neuroprotection induced by sevoflurane preconditioning. Anesthesiology 121:549–562. doi:10.1097/ALN.0000000000000314
Takarada-Iemata M, Kezuka D, Takeichi T, Ikawa M, Hattori T, Kitao Y, Hori O (2014) Deletion of N-myc downstream-regulated gene 2 attenuates reactive astrogliosis and inflammatory response in a mouse model of cortical stab injury. J Neurochem 130:374–387. doi:10.1111/jnc.12729
Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J et al (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106:342–347. doi:10.1002/ijc.11228
Takeichi T, Takarada-Iemata M, Hashida K, Sudo H, Okuda T, Kokame K, Hatano T, Takanashi M et al (2011) The effect of Ndrg2 expression on astroglial activation. Neurochem Int 59:21–27. doi:10.1016/j.neuint.2011.03.019
Swanson RA, Ying W, Kauppinen TM (2004) Astrocyte influences on ischemic neuronal death. Curr Mol Med 4:193–205. doi:10.2174/1566524043479185
Acknowledgments
This study was supported by the Natural Science Foundation of China (81571279; 81371446; 81403451; 81370194), China Postdoctoral Science Foundation (2014M562560; 2015T81110), and Beijing Natural Science Foundation (7154242). We thank American Journal Experts (AJE) for assisting in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
All animal experimental procedures followed a protocol approved by the Ethics Committee for Animal Experimentation of the Fourth Military Medical University, China.
Additional information
Yu-Long Ma, Li-xia Zhang and Guang-lin Liu contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Figure 1
Fluorescence microscopy showing the transduction efficiency in M1800 cells that were inoculated with Lenti-GFP for 72 h. A. Infected M1800 cells viewed using a normal microscope. B. Infected M1800 cells viewed via fluorescence microscopy. The cells with green fluorescence were successfully infected with Lenti-GFP. Bar = 50 μm. (GIF 83 kb)
Supplementary Figure 2
Effect of the lentivirus on NDRG2 expression. (A) The data are shown as the mean ± S.D.; **p < 0.01 vs. the KD-NC group; ###p < 0.001 vs. the OE-NC group. (B) Representative photographs showing the expression of NDRG2 protein in the various groups. (GIF 38 kb)
Rights and permissions
About this article
Cite this article
Ma, YL., Zhang, Lx., Liu, Gl. et al. N-Myc Downstream-Regulated Gene 2 (Ndrg2) Is Involved in Ischemia–Hypoxia-Induced Astrocyte Apoptosis: a Novel Target for Stroke Therapy. Mol Neurobiol 54, 3286–3299 (2017). https://doi.org/10.1007/s12035-016-9814-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-016-9814-5